ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
ApexOnco Front Page
Recent articles
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Another SERD catalyst and the son of Darzalex take centre stage.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
Giredestrant will soon become the first oral SERD to yield first-line data.
But this adds another complexity, and has camizestrant really scored a first-line win?
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
